Pfizer Inc. PFE
Healthcare · Drug Manufacturers - General · United States · S&P 500
Based on the available data, Pfizer Inc. gets an algorithmic score of 55/100. It trades at 28.72 $, with a bullish technical trend (RSI 67.0) and 23.2% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- Attractive free-cash-flow yield (5.5%).
- Low valuation (P/E 9.9).
- Low beta (0.37): defensive profile.
- Meaningful dividend (5.99%).
Weaknesses
- Shrinking revenue (-14.8% per year).
Fundamentals
| P/E | 37.79 |
| Forward P/E | 9.91 |
| PEG | 12.89 |
| P/B | 1.92 |
| EV/EBITDA | 8.50 |
| P/S | 2.57 |
| ROE % | 5.01 |
| ROA % | 5.78 |
| Gross margin % | 74.72 |
| Operating margin % | 27.88 |
| Net margin % | 6.80 |
| Revenue growth % (y/y) | 2.60 |
| Revenue CAGR % | -14.80 |
| Earnings CAGR % | -37.20 |
| Debt/Equity % | 74.25 |
| Current ratio | 1.27 |
| FCF yield % | 5.54 |
| Dividend yield % | 5.99 |
| Payout % | 226.32 |
Returns
| 1 month | +2.7 % |
| 3 months | +21.4 % |
| 6 months | +7.0 % |
| YTD | +19.9 % |
| 1 year | +29.4 % |
| 3 years | +6.5 % |
| 5 years | -14.8 % |
Risk
| 1-year volatility | 23.2 % |
| Beta | 0.37 |
| 5-year max drawdown | -59.0 % |
| Sharpe 1A | 1.05 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.